Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study

BACKGROUND: While programmed cell death protein 1 (PD-1) blockade has demonstrated varying effectiveness in treating advanced esophageal squamous cell carcinoma (ESCC), no validated prognostic factors have been identified. Immune-related adverse events (irAEs) have been shown to predict immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ya-Nan, Cong, Dan, Zhang, Wenlong, Jia, Yuanyuan, Bai, Yuansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186529/
https://www.ncbi.nlm.nih.gov/pubmed/37201088
http://dx.doi.org/10.21037/jgo-23-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186529/
https://www.ncbi.nlm.nih.gov/pubmed/37201088
http://dx.doi.org/10.21037/jgo-23-75

Ejemplares similares